This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Abbott, Bank of America, PayPal, The Procter & Gamble Co and Boeing
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Bank of America, PayPal, The Procter & Gamble Co and Boeing
Abbott (ABT) Stock Moves -1.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $110.33, marking a -1.16% move from the previous day.
Top Research Reports for Abbott, Bank of America & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Bank of America (BAC), and PayPal (PYPL).
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $110.48, marking a +0.52% move from the previous day.
Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 heart pump can significantly enhance quality of life and reduce adverse events.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $110 in the latest trading session, marking a +0.65% move from the prior day.
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
by Riya Anand
MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
Walgreens (WBA) Divests Alliance Healthcare Business for $6.5B
by Zacks Equity Research
Walgreens (WBA) will increase focus on core retail pharmacy business and bring better healthcare offerings to patients and customers with the divestment.
The Zacks Analyst Blog Highlights: Citigroup, Abbott Laboratories, Intercontinental Exchange, BCE and AutoZone
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Citigroup, Abbott Laboratories, Intercontinental Exchange, BCE and AutoZone
Abbott (ABT) Downgrades 2021 Outlook on Lower Testing Demand
by Zacks Equity Research
Abbott's (ABT) revised 2021 forecast continues to reflect strong, double-digit EPS growth despite lower COVID-19 testing demand.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $106.90, moving +1.05% from the previous trading session.
Top Analyst Reports for Citigroup, Abbott & Intercontinental Exchange
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Citigroup Inc. (C), Abbott Laboratories (ABT) and Intercontinental Exchange, Inc. (ICE).
Company News for Jun 2, 2021
by Zacks Equity Research
Companies In The News Are: ABT, CLDR, KKR, CGC, NIO.
Quest Diagnostics (DGX) New Pact Targets Health Inequity Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with SAHRC will help improve the health and quality of lives of underserved communities.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $115.69, marking a -0.91% move from the previous day.
Abbott (ABT) Organic Growth Strong, Pediatric Nutrition Down
by Zacks Equity Research
Within Medical Device, Abbott (ABT) is facing challenging conditions in terms of procedure volume.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.13, marking a -0.57% move from the previous day.
Abbott (ABT) Down 5.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Receives CE Mark for Latest Navitor TAVI System
by Zacks Equity Research
Abbott's (ABT) latest-generation Navitor TAVI system features improvements to reduce or eliminate a backflow of blood around valve implants.
Quest Diagnostics (DGX) Expands COVID-19 Test Eligibility
by Zacks Equity Research
This zero out-of-pocket option applies to Quest Diagnostics' (DGX) molecular laboratory (PCR/NAAT) as well as rapid antigen testing.
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $118.51 in the latest trading session, marking a +0.83% move from the prior day.
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.